AUTHOR=Wang Chao , Yin Lianfang 

TITLE=Xiaoyaosan formula augments adjuvant therapy and enhances postoperative breast cancer care

JOURNAL=Frontiers in Pharmacology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1388646

DOI=10.3389/fphar.2024.1388646

ISSN=1663-9812

ABSTRACT=<sec><title>Introduction</title><p>Xiaoyaosan (XYS), a traditional Chinese formula, not only has good antitumor effects but also attenuates distress, anorexia, and quality of life (QoL) by regulating neurology, the microbiota, immunology, and oxidative stress. This study aimed to assess the effect of XYS on QoL, psychological pressure, and spiritual well-being in breast cancer patients undergoing adjuvant chemotherapy.</p></sec><sec><title>Methods</title><p>This prospective cohort study enrolled 176 postoperative breast cancer patients who received adjuvant chemotherapy combined with (n = 81) or without (n = 95) XYS for comparison. The Quality-of-Life Questionnaire Core-30 (QLQ-C30), Hospital Anxiety and Depression Scale (HADS), University of California Los Angeles (UCLA-LS), and Functional Assessment of Chronic Illness Therapy–Spiritual Well-being (FACIT–Sp) scores were evaluated before adjuvant chemotherapy (T<sub>0</sub>) and after the first (T<sub>1</sub>), second (T<sub>2</sub>), third (T<sub>3</sub>), and fourth cycles (T<sub>4</sub>) of adjuvant chemotherapy.</p></sec><sec><title>Results</title><p>XYS improved the QLQ-C30 score at T<sub>2</sub> (<italic>p</italic> = 0.043), T<sub>3</sub> (<italic>p</italic> = 0.021), and T<sub>4</sub> (<italic>p</italic> = 0.040) and the QLQ-C30 score at T<sub>4</sub> (<italic>p</italic> = 0.027); moreover, XYS attenuated the QLQ-C30 score at T<sub>2</sub> (<italic>p</italic> = 0.040), T<sub>3</sub> (<italic>p</italic> = 0.023), and T<sub>4</sub> (<italic>p</italic> = 0.027). Regarding distress, XYS reduced the HADS-anxiety score at T<sub>2</sub> (<italic>p</italic> = 0.010), T<sub>3</sub> (<italic>p</italic> = 0.025), and T<sub>4</sub> (<italic>p</italic> = 0.019) and the HADS-defined anxiety score at T<sub>3</sub> (<italic>p</italic> = 0.038). XYS also decreased the HADS-depression score at T<sub>2</sub> (<italic>p</italic> = 0.016), T<sub>3</sub> (<italic>p</italic> = 0.018), and T<sub>4</sub> (<italic>p</italic> = 0.017) and the HADS-defined depression rate at T<sub>2</sub> (<italic>p</italic> = 0.047), T<sub>3</sub> (<italic>p</italic> = 0.012), and T<sub>4</sub> (<italic>p</italic> = 0.013). In addition, XYS decreased the UCLA-LS at T<sub>2</sub> (<italic>p</italic> = 0.023) but enhanced the FACIT-Sp at T<sub>2</sub> (<italic>p</italic> = 0.029) and T<sub>4</sub> (<italic>p</italic> = 0.026). Furthermore, after adjustment via propensity score matching, most of the significant findings remained.</p></sec><sec><title>Discussion</title><p>The addition of XYS to adjuvant chemotherapy improved QoL, psychological health, and spiritual well-being in breast cancer patients.</p></sec>